Innate Pharma Stock Analysis

Innate Stock Analysis Notes

The company recorded a loss per share of 0.65. Innate Pharma had not issued any dividends in recent years. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. Innate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people. To learn more about Innate Pharma call Mondher MD at 33 4 30 30 30 30 or check out https://www.innate-pharma.com.

Innate Pharma Investment Alerts

Innate Largest EPS Surprises

View All Earnings Estimates

Innate Stock Institutional Investors

Note, although Innate Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Innate Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 168.37 M.

Innate Profitablity

Management Efficiency

Innate Pharma has return on total asset (ROA) of (0.2592) % which means that it has lost $0.2592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7137) %, meaning that it created substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.49. The current year's Return On Capital Employed is expected to grow to -0.56. At present, Innate Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 53.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 8.5 M.

Technical Drivers

As of the 12th of February 2026, Innate Pharma retains the Risk Adjusted Performance of 0.0087, downside deviation of 3.17, and Market Risk Adjusted Performance of (0.03). Innate Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Innate Pharma Price Movement Analysis

Innate Pharma Outstanding Bonds

Innate Pharma Predictive Daily Indicators

Innate Pharma Forecast Models

Innate Pharma's time-series forecasting models are one of many Innate Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Innate Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Innate Pharma Bond Ratings

Innate Pharma financial ratings play a critical role in determining how much Innate Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Innate Pharma's borrowing costs.

Innate Pharma Debt to Cash Allocation

Innate Pharma currently holds 31 M in liabilities with Debt to Equity (D/E) ratio of 0.37, which is about average as compared to similar companies. Innate Pharma has a current ratio of 2.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Innate Pharma's use of debt, we should always consider it together with its cash and equity.

Innate Pharma Total Assets Over Time

Innate Pharma Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Innate Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Innate Pharma Debt Ratio

27.0

It appears most of the Innate Pharma's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Innate Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Innate Pharma, which in turn will lower the firm's financial flexibility.

Innate Pharma Corporate Bonds Issued

Innate Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Innate Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Innate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Innate Pharma. By using and applying Innate Stock analysis, traders can create a robust methodology for identifying Innate entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Innate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Innate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Innate Pharma stock analysis indicators help investors evaluate how Innate Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Innate Pharma shares will generate the highest return on investment. By understating and applying Innate Pharma stock analysis, traders can identify Innate Pharma position entry and exit signals to maximize returns.

When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.